Most CFOs treat a clean share sale as a capital gains problem for the sellers and a completion-accounts problem for the buyer. CooperVision Lens Care Limited v HMRC [2026] UKFTT 324 (TC) is a reminder that, once employee or director equity is in the cap table, differential exit pricing can turn into a company PAYE and Class 1 NIC problem years later — with a six-year assessment window if HMRC can show carelessness.
The numbers are large enough to focus the mind. Sauflon Pharmaceuticals (later CooperVision Lens Care) was sold in August 2014 for roughly £663 million. Majority employee/director sellers took about £2,850 a share. Minority institutional sellers took about £1,539–£1,555 a share. The sellers paid capital gains tax. HMRC said part of the majority premium was employment income under Chapter 3D of Part 7 ITEPA 2003, and that the employer should have operated PAYE and accounted for Class 1 NICs. The First-tier Tribunal largely agreed.
If you run PE-backed management equity, founder-manager secondaries, or any exit where employee shareholders take more per share than pure financial sellers, this case belongs in your pre-signing checklist — not in the post-completion lessons-learned file.
What Chapter 3D actually taxes
Chapter 3D is simple in structure and brutal in application. Where employment-related securities are disposed of for more than market value, the excess counts as employment income. On a corporate exit the shares are almost always readily convertible assets, so section 698 ITEPA puts the employer on the hook for PAYE. Employer NICs follow. Fail to recover the employee tax in time and you can face a further section 222 “tax on tax” charge.
Market value is not “whatever the sellers privately agreed among themselves.” It is the open-market value under the TCGA tests: what a hypothetical willing buyer would pay for the rights attaching to the shares. Personal leverage, dispute settlements, warranty allocation fights and majority bargaining power do not inflate that value unless they are intrinsic rights of the shares themselves.
That is the line drawn by the Supreme Court in Grays Timber Products Ltd v HMRC [2010] UKSC 4, and it is the line the FTT applied again in CooperVision. One buyer. One global price for 100% of the equity. Internal redistribution among sellers is not a second market.
Why the shares stayed “employment-related” decades later
The company argued that historic options and acquisitions were commercial, not employment-linked. The tribunal was unimpressed for three of the four share tranches.
Key points from the decision and the case summary on Find Case Law:
- Options granted as part of recruiting or retaining MD/FD leadership were employment-linked even where documents tried to say otherwise.
- Later conversions, renegotiations and replacement options did not break the chain. Under the ERS rules, replacement securities can inherit the original employment connection.
- Transfer to a spouse who is an “associated person” keeps the employment-related character.
- Only a fourth tranche — offered on a true shareholder basis to employee and non-employee holders alike — escaped the ERS net on the tribunal’s analysis.
The practical message for CFOs is not subtle. Equity issued to executives in the 1980s, 1990s or 2000s can still be ERS on a 2020s exit. “We always treated this as founder equity” is not a defence if the opportunity came from the employer and sat inside the remuneration package.
The deeming rule matters here. Where the employer (or a connected person) makes the opportunity available, the securities are treated as employment-related unless a narrow domestic/family exception applies. The Supreme Court reinforced that bright-line approach in HMRC v Vermilion Holdings Ltd [2023] UKSC 3. Do not build your exit model on a soft causation story if the employer put the opportunity on the table.
Market value: the differential that became payroll
CooperVision’s sellers had a commercial narrative: different investor groups negotiated different prices at arm’s length, so those prices were market value. HMRC’s counter was simpler and, on these facts, stronger. CooperVision Holdings paid one price for the whole company. How the sellers then divided the pot reflected bargaining power, litigation risk, fund timing pressure and warranty allocation — not different intrinsic share rights.
The FTT accepted that analysis. Market value was the pro-rata slice of the global price. The excess taken by the majority employee/director sellers over that pro-rata value was Chapter 3D income — except on the non-ERS fourth tranche.
Moore Kingston Smith’s technical note is worth circulating to your deal team. Two valuation products were in play: an independent expert report and adviser material. The tribunal criticised both for treating the private allocation as if it were the open-market price, and for leaning on personal rights that a hypothetical buyer would not pay for. That is the Gray’s Timber problem in modern M&A clothing.
If your data room includes a “proceeds waterfall” that pays management more per share than the PE or minority stack without a hardwired class right, preference or hurdle in the articles/SHA, assume HMRC can recharacterise the excess as employment income until someone proves otherwise.
The carelessness point is the CFO point
This case is not only about the technical charge. It is about time limits and governance.
HMRC’s Regulation 80 PAYE determination was issued in February 2021 for a 2014/15 disposal — outside the ordinary four-year window. To get six years, HMRC had to show the tax loss was brought about carelessly by the employer. The tribunal held that it was.
On the findings summarised by Ross Martin and the judgment itself, the company’s tax lead leaned on a memorandum that itself flagged significant risk, did not commission independent specialist UK employment-tax advice, did not pressure-test the adviser’s caveats hard enough, and did not keep the PAYE risk under review after completion. That package failed the “reasonable care” standard.
Translate that into board language:
- A risk memo is not a green light.
- “Advisers signed off CGT for the sellers” is not the same as “employer PAYE/NIC position signed off.”
- If the memo says the Chapter 3D risk is material, the CFO needs a documented decision, a valuation that can survive Gray’s Timber, and a payroll operating plan — or a clear, reasoned decision not to operate PAYE with contingency funding if HMRC later disagrees.
Carelessness is not only a penalties issue. It is what keeps a 2014 exit alive as a 2021 assessment.
What PE and corporate CFOs should do on the next deal
1. Map every employee/director share and option back to origin. Date, grantor, employment condition, leaver provisions, replacements, spouse transfers. Build an ERS register, not a spreadsheet afterthought.
2. Price the exit on intrinsic share rights, not personalities. If management is to receive more economics, put it in the instrument: growth shares, ratchet, preferred return, bonus pool, or a properly documented management incentive plan. Do not invent a higher per-share price at the SPA allocation table and hope CGT labelling sticks.
3. Separate seller tax from employer tax. Sellers can be right about their CGT filings and the company can still have a PAYE failure. Get employment-tax counsel on the employer side with a written opinion that addresses Chapter 3D, readily convertible assets, and NIC.
4. Force the valuation question early. Instruct valuers on the statutory hypothetical purchaser basis. Tell them explicitly not to treat personal side deals as share rights. If they cannot support equal per-share MV on a 100% sale, quantify the Chapter 3D delta before heads of terms harden.
5. Build payroll into the completion mechanics. Where a 3D charge is more likely than not, operate PAYE, hold back proceeds if needed, and document recovery from the employee sellers. Leaving it as “sellers will sort CGT” is how Regulation 80 determinations are born.
6. Keep the paper. Risk memos, challenge emails, board minutes, valuation instructions, and the decision trail. In CooperVision, the quality of the care process mattered as much as the technical answer.
7. On buy-side diligence, price the stub risk. Historic management equity with uneven exit waterfalls is a contingent employment-tax liability sitting with the target employer. Warranty and indemnity cover, specific indemnities, and escrow are commercial tools, not optional nice-to-haves.
Where this sits in the wider employment-tax stack
Chapter 3D is only one moving part. HMRC’s Employment Related Securities Manual on disposals above market value sits alongside annual ERS online reporting, PAYE real-time information, and the wider Part 7 architecture for restricted securities, convertible securities and options. The NIC treatment of securities income needs to be run in parallel, not as a cleanup item.
For groups already wrestling with mandatory benefits-in-kind payrolling from April 2027, the cultural point is the same: employment tax is moving from annual afterthought to in-year cash and controls. Exit equity is no exception.
Bottom line
CooperVision is not a quirky contact-lens case. It is a controls case. Differential pricing among sellers does not create market value. Historic executive equity does not age out of the ERS rules just because the company has grown up. And a cautious memo you fail to act on can hand HMRC an extra two years to assess the employer.
If you have a live process, or a portfolio company preparing one, do three things this week: pull the ERS origin file, stress-test any non-pro-rata waterfall against Gray’s Timber, and get a written employer-side Chapter 3D opinion before the SPA locks the economics. The tax is easier to structure before signing than to payroll after HMRC arrives.
Further reading: the full FTT decision on Find Case Law, HMRC’s Chapter 3D PAYE note (EIM12270), the Gray’s Timber valuation analysis in ERSM80130, and the Moore Kingston Smith case note.